Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine.
Identifieur interne : 005656 ( Main/Exploration ); précédent : 005655; suivant : 005657Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine.
Auteurs : David K. Simon [Singapour] ; Cai Wu ; Barbara C. Tilley ; Anne-Marie Wills ; Michael J. Aminoff ; Jacquelyn Bainbridge ; Robert A. Hauser ; Jay S. Schneider ; Saloni Sharma ; Carlos Singer ; Caroline M. Tanner ; Daniel Truong ; Pei Shieen WongSource :
- Clinical neuropharmacology [ 1537-162X ]
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Caffeine, Central Nervous System Stimulants.
- chemical , therapeutic use : Creatine.
- drug therapy : Parkinson Disease.
- Disease Progression, Drug Interactions, Female, Humans, Male, Middle Aged.
Abstract
Increased caffeine intake is associated with a lower risk of Parkinson disease (PD) and is neuroprotective in mouse models of PD. However, in a previous study, an exploratory analysis suggested that, in patients taking creatine, caffeine intake was associated with a faster rate of progression. In the current study, we investigated the association of caffeine with the rate of progression of PD and the interaction of this association with creatine intake.
DOI: 10.1097/WNF.0000000000000102
PubMed: 26366971
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000423
- to stream PubMed, to step Curation: 000423
- to stream PubMed, to step Checkpoint: 000423
- to stream Ncbi, to step Merge: 001D09
- to stream Ncbi, to step Curation: 001D09
- to stream Ncbi, to step Checkpoint: 001D09
- to stream Main, to step Merge: 006073
- to stream Main, to step Curation: 005656
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine.</title><author><name sortKey="Simon, David K" sort="Simon, David K" uniqKey="Simon D" first="David K" last="Simon">David K. Simon</name><affiliation wicri:level="1"><nlm:affiliation>*Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; †Department of Biostatistics, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX; ‡Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA; §Department of Neurology, University of California, San Francisco, CA; ∥Department of Clinical Pharmacy and Neurology, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO; ¶Department of Neurology, University of South Florida, Tampa, FL; #Department of Pathology, Anatomy and Cell Biology, Parkinson's Disease Research Unit, Thomas Jefferson University, Philadelphia, PA; **Clinical Trials Coordination Center, University of Rochester Medical Center, Rochester, NY; ††Department of Neurology, Miller School of Medicine, University of Miami, Miami, FL; ‡‡Parkinson's Disease Research Education and Clinical Center, San Francisco Veteran's Affairs Medical Center, San Francisco, CA; §§The Parkinson's and Movement Disorder Institute, Fountain Valley, CA; and ∥∥Singapore General Hospital, Singapore.</nlm:affiliation><country xml:lang="fr">Singapour</country><wicri:regionArea>*Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; †Department of Biostatistics, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX; ‡Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA; §Department of Neurology, University of California, San Francisco, CA; ∥Department of Clinical Pharmacy and Neurology, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO; ¶Department of Neurology, University of South Florida, Tampa, FL; #Department of Pathology, Anatomy and Cell Biology, Parkinson's Disease Research Unit, Thomas Jefferson University, Philadelphia, PA; **Clinical Trials Coordination Center, University of Rochester Medical Center, Rochester, NY; ††Department of Neurology, Miller School of Medicine, University of Miami, Miami, FL; ‡‡Parkinson's Disease Research Education and Clinical Center, San Francisco Veteran's Affairs Medical Center, San Francisco, CA; §§The Parkinson's and Movement Disorder Institute, Fountain Valley, CA; and ∥∥Singapore General Hospital</wicri:regionArea><wicri:noRegion>CA; and ∥∥Singapore General Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Wu, Cai" sort="Wu, Cai" uniqKey="Wu C" first="Cai" last="Wu">Cai Wu</name></author><author><name sortKey="Tilley, Barbara C" sort="Tilley, Barbara C" uniqKey="Tilley B" first="Barbara C" last="Tilley">Barbara C. Tilley</name></author><author><name sortKey="Wills, Anne Marie" sort="Wills, Anne Marie" uniqKey="Wills A" first="Anne-Marie" last="Wills">Anne-Marie Wills</name></author><author><name sortKey="Aminoff, Michael J" sort="Aminoff, Michael J" uniqKey="Aminoff M" first="Michael J" last="Aminoff">Michael J. Aminoff</name></author><author><name sortKey="Bainbridge, Jacquelyn" sort="Bainbridge, Jacquelyn" uniqKey="Bainbridge J" first="Jacquelyn" last="Bainbridge">Jacquelyn Bainbridge</name></author><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A" last="Hauser">Robert A. Hauser</name></author><author><name sortKey="Schneider, Jay S" sort="Schneider, Jay S" uniqKey="Schneider J" first="Jay S" last="Schneider">Jay S. Schneider</name></author><author><name sortKey="Sharma, Saloni" sort="Sharma, Saloni" uniqKey="Sharma S" first="Saloni" last="Sharma">Saloni Sharma</name></author><author><name sortKey="Singer, Carlos" sort="Singer, Carlos" uniqKey="Singer C" first="Carlos" last="Singer">Carlos Singer</name></author><author><name sortKey="Tanner, Caroline M" sort="Tanner, Caroline M" uniqKey="Tanner C" first="Caroline M" last="Tanner">Caroline M. Tanner</name></author><author><name sortKey="Truong, Daniel" sort="Truong, Daniel" uniqKey="Truong D" first="Daniel" last="Truong">Daniel Truong</name></author><author><name sortKey="Wong, Pei Shieen" sort="Wong, Pei Shieen" uniqKey="Wong P" first="Pei Shieen" last="Wong">Pei Shieen Wong</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>2015 Sep-Oct</MedlineDate></PubDate></date><idno type="RBID">pubmed:26366971</idno><idno type="pmid">26366971</idno><idno type="doi">10.1097/WNF.0000000000000102</idno><idno type="wicri:Area/PubMed/Corpus">000423</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000423</idno><idno type="wicri:Area/PubMed/Curation">000423</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000423</idno><idno type="wicri:Area/PubMed/Checkpoint">000423</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000423</idno><idno type="wicri:Area/Ncbi/Merge">001D09</idno><idno type="wicri:Area/Ncbi/Curation">001D09</idno><idno type="wicri:Area/Ncbi/Checkpoint">001D09</idno><idno type="wicri:Area/Main/Merge">006073</idno><idno type="wicri:Area/Main/Curation">005656</idno><idno type="wicri:Area/Main/Exploration">005656</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine.</title><author><name sortKey="Simon, David K" sort="Simon, David K" uniqKey="Simon D" first="David K" last="Simon">David K. Simon</name><affiliation wicri:level="1"><nlm:affiliation>*Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; †Department of Biostatistics, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX; ‡Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA; §Department of Neurology, University of California, San Francisco, CA; ∥Department of Clinical Pharmacy and Neurology, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO; ¶Department of Neurology, University of South Florida, Tampa, FL; #Department of Pathology, Anatomy and Cell Biology, Parkinson's Disease Research Unit, Thomas Jefferson University, Philadelphia, PA; **Clinical Trials Coordination Center, University of Rochester Medical Center, Rochester, NY; ††Department of Neurology, Miller School of Medicine, University of Miami, Miami, FL; ‡‡Parkinson's Disease Research Education and Clinical Center, San Francisco Veteran's Affairs Medical Center, San Francisco, CA; §§The Parkinson's and Movement Disorder Institute, Fountain Valley, CA; and ∥∥Singapore General Hospital, Singapore.</nlm:affiliation><country xml:lang="fr">Singapour</country><wicri:regionArea>*Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; †Department of Biostatistics, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX; ‡Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA; §Department of Neurology, University of California, San Francisco, CA; ∥Department of Clinical Pharmacy and Neurology, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO; ¶Department of Neurology, University of South Florida, Tampa, FL; #Department of Pathology, Anatomy and Cell Biology, Parkinson's Disease Research Unit, Thomas Jefferson University, Philadelphia, PA; **Clinical Trials Coordination Center, University of Rochester Medical Center, Rochester, NY; ††Department of Neurology, Miller School of Medicine, University of Miami, Miami, FL; ‡‡Parkinson's Disease Research Education and Clinical Center, San Francisco Veteran's Affairs Medical Center, San Francisco, CA; §§The Parkinson's and Movement Disorder Institute, Fountain Valley, CA; and ∥∥Singapore General Hospital</wicri:regionArea><wicri:noRegion>CA; and ∥∥Singapore General Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Wu, Cai" sort="Wu, Cai" uniqKey="Wu C" first="Cai" last="Wu">Cai Wu</name></author><author><name sortKey="Tilley, Barbara C" sort="Tilley, Barbara C" uniqKey="Tilley B" first="Barbara C" last="Tilley">Barbara C. Tilley</name></author><author><name sortKey="Wills, Anne Marie" sort="Wills, Anne Marie" uniqKey="Wills A" first="Anne-Marie" last="Wills">Anne-Marie Wills</name></author><author><name sortKey="Aminoff, Michael J" sort="Aminoff, Michael J" uniqKey="Aminoff M" first="Michael J" last="Aminoff">Michael J. Aminoff</name></author><author><name sortKey="Bainbridge, Jacquelyn" sort="Bainbridge, Jacquelyn" uniqKey="Bainbridge J" first="Jacquelyn" last="Bainbridge">Jacquelyn Bainbridge</name></author><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A" last="Hauser">Robert A. Hauser</name></author><author><name sortKey="Schneider, Jay S" sort="Schneider, Jay S" uniqKey="Schneider J" first="Jay S" last="Schneider">Jay S. Schneider</name></author><author><name sortKey="Sharma, Saloni" sort="Sharma, Saloni" uniqKey="Sharma S" first="Saloni" last="Sharma">Saloni Sharma</name></author><author><name sortKey="Singer, Carlos" sort="Singer, Carlos" uniqKey="Singer C" first="Carlos" last="Singer">Carlos Singer</name></author><author><name sortKey="Tanner, Caroline M" sort="Tanner, Caroline M" uniqKey="Tanner C" first="Caroline M" last="Tanner">Caroline M. Tanner</name></author><author><name sortKey="Truong, Daniel" sort="Truong, Daniel" uniqKey="Truong D" first="Daniel" last="Truong">Daniel Truong</name></author><author><name sortKey="Wong, Pei Shieen" sort="Wong, Pei Shieen" uniqKey="Wong P" first="Pei Shieen" last="Wong">Pei Shieen Wong</name></author></analytic><series><title level="j">Clinical neuropharmacology</title><idno type="eISSN">1537-162X</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Caffeine (adverse effects)</term><term>Central Nervous System Stimulants (adverse effects)</term><term>Creatine (therapeutic use)</term><term>Disease Progression</term><term>Drug Interactions</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Caffeine</term><term>Central Nervous System Stimulants</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Creatine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Disease Progression</term><term>Drug Interactions</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Increased caffeine intake is associated with a lower risk of Parkinson disease (PD) and is neuroprotective in mouse models of PD. However, in a previous study, an exploratory analysis suggested that, in patients taking creatine, caffeine intake was associated with a faster rate of progression. In the current study, we investigated the association of caffeine with the rate of progression of PD and the interaction of this association with creatine intake.</div></front></TEI><affiliations><list><country><li>Singapour</li></country></list><tree><noCountry><name sortKey="Aminoff, Michael J" sort="Aminoff, Michael J" uniqKey="Aminoff M" first="Michael J" last="Aminoff">Michael J. Aminoff</name><name sortKey="Bainbridge, Jacquelyn" sort="Bainbridge, Jacquelyn" uniqKey="Bainbridge J" first="Jacquelyn" last="Bainbridge">Jacquelyn Bainbridge</name><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A" last="Hauser">Robert A. Hauser</name><name sortKey="Schneider, Jay S" sort="Schneider, Jay S" uniqKey="Schneider J" first="Jay S" last="Schneider">Jay S. Schneider</name><name sortKey="Sharma, Saloni" sort="Sharma, Saloni" uniqKey="Sharma S" first="Saloni" last="Sharma">Saloni Sharma</name><name sortKey="Singer, Carlos" sort="Singer, Carlos" uniqKey="Singer C" first="Carlos" last="Singer">Carlos Singer</name><name sortKey="Tanner, Caroline M" sort="Tanner, Caroline M" uniqKey="Tanner C" first="Caroline M" last="Tanner">Caroline M. Tanner</name><name sortKey="Tilley, Barbara C" sort="Tilley, Barbara C" uniqKey="Tilley B" first="Barbara C" last="Tilley">Barbara C. Tilley</name><name sortKey="Truong, Daniel" sort="Truong, Daniel" uniqKey="Truong D" first="Daniel" last="Truong">Daniel Truong</name><name sortKey="Wills, Anne Marie" sort="Wills, Anne Marie" uniqKey="Wills A" first="Anne-Marie" last="Wills">Anne-Marie Wills</name><name sortKey="Wong, Pei Shieen" sort="Wong, Pei Shieen" uniqKey="Wong P" first="Pei Shieen" last="Wong">Pei Shieen Wong</name><name sortKey="Wu, Cai" sort="Wu, Cai" uniqKey="Wu C" first="Cai" last="Wu">Cai Wu</name></noCountry><country name="Singapour"><noRegion><name sortKey="Simon, David K" sort="Simon, David K" uniqKey="Simon D" first="David K" last="Simon">David K. Simon</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005656 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005656 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26366971
|texte= Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26366971" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |